IRIS
Caffo, Orazio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.152
AS - Asia 1.046
EU - Europa 841
SA - Sud America 156
AF - Africa 31
OC - Oceania 3
Totale 3.229
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.118
SG - Singapore 403
IT - Italia 306
VN - Vietnam 186
CN - Cina 184
DE - Germania 132
BR - Brasile 116
FI - Finlandia 95
RU - Federazione Russa 95
HK - Hong Kong 74
KR - Corea 64
FR - Francia 41
GB - Regno Unito 40
IN - India 27
LV - Lettonia 23
ID - Indonesia 22
SE - Svezia 19
NL - Olanda 16
BD - Bangladesh 14
CA - Canada 14
IQ - Iraq 14
AR - Argentina 13
PL - Polonia 13
AT - Austria 12
IE - Irlanda 12
MX - Messico 12
SA - Arabia Saudita 10
UA - Ucraina 10
ZA - Sudafrica 10
JP - Giappone 9
TR - Turchia 7
EC - Ecuador 6
VE - Venezuela 6
CZ - Repubblica Ceca 5
JO - Giordania 5
PK - Pakistan 5
CO - Colombia 4
ES - Italia 4
NP - Nepal 4
PH - Filippine 4
CL - Cile 3
EG - Egitto 3
GT - Guatemala 3
KE - Kenya 3
MA - Marocco 3
MY - Malesia 3
PE - Perù 3
UY - Uruguay 3
AL - Albania 2
BG - Bulgaria 2
DZ - Algeria 2
HU - Ungheria 2
LT - Lituania 2
MK - Macedonia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AO - Angola 1
AU - Australia 1
BE - Belgio 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
KG - Kirghizistan 1
LB - Libano 1
LS - Lesotho 1
LU - Lussemburgo 1
LY - Libia 1
MT - Malta 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TW - Taiwan 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 3.229
Salva come PNG Salva come JPEG
Città #
Singapore 286
San Jose 147
Trento 130
Ashburn 121
Munich 103
Helsinki 74
Hong Kong 67
Seoul 62
Council Bluffs 58
Santa Clara 58
Dallas 54
Ho Chi Minh City 54
Los Angeles 50
Fairfield 41
Hanoi 37
Chandler 36
Columbus 35
Moscow 31
New York 31
Beijing 23
Riga 23
Chicago 21
Lauterbourg 21
Rome 21
The Dalles 21
Houston 19
Da Nang 17
Verona 17
Jacksonville 16
Milan 16
Orem 16
Wilmington 16
Ogden 15
Seattle 15
Princeton 13
Jakarta 12
Hefei 11
Nuremberg 11
St Louis 11
São Paulo 11
Cambridge 10
Shenzhen 10
Warsaw 10
Chennai 9
Mattarello 9
Salt Lake City 9
San Mateo 9
Woodbridge 9
Ann Arbor 8
London 8
North Bergen 8
Tokyo 8
Buffalo 7
Dublin 7
Frankfurt am Main 7
Lappeenranta 7
Vienna 7
Atlanta 6
Baghdad 6
Cincinnati 6
Denver 6
Jyväskylä 6
Paris 6
Redondo Beach 6
Toronto 6
Vicenza 6
Amman 5
Curitiba 5
Daiano 5
Falkenstein 5
Haiphong 5
Johannesburg 5
Manchester 5
Boardman 4
Boston 4
Can Tho 4
Como 4
Dammam 4
Detroit 4
Hải Dương 4
Istanbul 4
Phoenix 4
Shanghai 4
Wuxi 4
Brno 3
Bắc Giang 3
Bắc Ninh 3
Caracas 3
Dearborn 3
Dhaka 3
Guangzhou 3
Lanciano 3
Lima 3
Mexico City 3
Miami 3
Montreal 3
Nottingham 3
Quito 3
Rio de Janeiro 3
Riyadh 3
Totale 2.144
Salva come PNG Salva come JPEG
Nome #
A model-based framework to identify optimal administration protocols for immunotherapies in castration-resistance prostate cancer 255
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 160
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer 160
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? 150
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment 136
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation 130
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? 128
Integrating extracellular vesicle and circulating cell-free DNA analysis on a single plasma aliquot improves the detection of HER2 positivity in breast cancer patients 125
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations 117
Complete pathological response to pembrolizumab in pretreated pancreatic acinar cell carcinoma 116
TRPM8 levels determine tumor vulnerability to channel agonists. 115
1730P Electronic medical record (EMR)-assisted phone follow-up (PFU) for breast cancer survivors (CS) during COVID-19 pandemic: An Italian single institution experience 111
Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic: A Single Institution Experience 104
Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti PD1/PDL1 therapy 103
Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study 88
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis 85
Tissue microarrays in oncology. 66
Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature 63
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer 58
Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma 57
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 49
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis 47
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study 32
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 29
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives 29
The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma 28
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide 27
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? 27
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 26
Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases 26
Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials 25
Association of G8 screening tool with prognosis and survival in patients with non-small cell lung cancer: A retrospective analysis from a single institution 24
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab 24
Clinical, Diagnostic and Therapeutic Framework of mHSPC and nmCRPC: A Multidisciplinary Consensus Project of the Italian Society for Uro-Oncology (SIUrO) 23
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line 23
Radioligand Therapies (RLTs) and Healthcare System Readiness: From the Experience in GEP-NET, a Retrospective Analysis on DRG and Mobility to Improve the Accessibility to the Future RLT in Italy 23
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study 23
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study 23
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 22
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 21
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 21
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 21
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study) 21
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 21
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 20
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 20
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study 19
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study 19
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 19
Prostate Cancer Diagnosis and Treatment in Elderly Patients: A Cross-Sectional Survey Exploring Practice Patterns and Preferences of Uro-Oncologists in Northeast Italy 19
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 19
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 18
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study 18
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology 17
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) 17
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1) 17
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 17
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 17
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project 16
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 16
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives 15
The Expanding Role of Next-generation Imaging in Prostate Cancer Management: A Cross-sectional Survey Exploring the Clinical Practice of Uro-oncologists in North-Eastern Italy; On Behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est) 14
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021 14
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU) 14
Prognostic Value of p21WAF1 and p53 Expression in Breast Carcinoma: An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up 14
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 13
Prostate cancer: Screening and early detection 13
Darolutamide Maintenance in Patients With Metastatic Castration- Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 13
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study 10
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC 10
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. 9
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 9
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials 8
Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer 8
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 7
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 6
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 6
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone 5
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? 5
Pain and quality of life after surgery for breast cancer 4
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer 4
Totale 3.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 3 2 1
2021/202299 0 1 0 12 12 0 13 25 6 2 9 19
2022/202380 10 13 0 11 5 11 1 3 7 7 8 4
2023/202482 4 2 4 2 3 8 4 10 5 13 9 18
2024/2025814 13 11 43 108 49 88 86 58 94 104 41 119
2025/20262.251 104 47 141 204 137 87 237 74 724 496 0 0
Totale 3.451